1201687-89-9

Basic information

• Product Name: 2-(chloromethyl)-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
• Synonyms: 2-(chloromethyl)-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
• CAS NO: 1201687-89-9
• Molecular Weight: 196.639
• Mol File: 1201687-89-9.mol
• Article Data: 11

Chemical Properties

• Density: 1.43±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 2-(chloromethyl)-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(chloromethyl)-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine(1201687-89-9)
• EPA Substance Registry System: 2-(chloromethyl)-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine(1201687-89-9)

Safety Data

• Hazardous Substances Data: 1201687-89-9(Hazardous Substances Data)

Upstream product

• 446839-32-3 1-amino-4,6-dimethyl-1H-pyrimidin-2-ylidene-amnnoniunn 2,4,6-trinnethyl-benzenesulfonate 
• 96-34-4 methyl chloroacetate 
• 123-54-6 acetylacetone 
• 54535-00-1 (5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol 
• 87253-62-1 5,7-dimethyl-1,2,4-triazolo<1,5-a>pyrimidine-2-carboxylic acid 
• 767-15-7 2-Amino-4,6-dimethylpyrimidine 

Downstream Products

• 7637-33-4 2,5,7-Trimethyl-s-triazolo<1,5-a>pyrimidin 

Relevant articles and documents

Continuous flow enables metallaphotoredox catalysis in a medicinal chemistry setting: Accelerated optimization and library execution of a reductive coupling between benzylic chlorides and aryl bromides

Continuous flow has been used widely in process chemistry and academic settings for various applications. However, initial reaction discovery has generally remained "batch-exclusive" despite the existence of efficient, reproducible flow systems. We hereby disclose a workflow to bridge the gap between early medicinal chemistry efforts and process-scale development, showcased by the discovery and optimization of a metallaphotoredox-catalyzed cross-coupling between benzylic chlorides and aryl bromides, followed by two library syntheses of complex drug-like compounds.

Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B

The hepatitis C virus (HCV) NS5B polymerase is an attractive target for the development of novel and selective inhibitors of HCV replication. In this paper, the design, synthesis, and preliminary SAR studies of novel inhibitors of HCV NS5B polymerase based on the structure of tegobuvir have been described. The efforts to optimize the antiviral potency and reduce the treatment side effects with respect to genotype 1b resulted in the discovery of compound 3, which exhibited an EC50 of 1.163 nM and a CC50 >200 nM in a cell-based HCV replicon system assay. Additionally, testing for inhibition of the hERG channel showed a marked improvement over tegobuvir and the pharmacokinetic properties of compound 3 indicated that it was worthy of further investigation as a non-nucleoside inhibitor of HCV NS5B polymerase.

NOVEL PHENYLIMIDAZOLE DERIVATIVE AS PDE10A ENZYME INHIBITOR

This invention provides the compound 5,8-Dimethyl-2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]thazolo[1,5-a]pyrazine and pharmaceutically acceptable acid addition salts thereof.